Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer
- PMID: 31023619
- DOI: 10.1016/j.therap.2019.03.010
Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer
Keywords: Kadcyla; Liver injury; Liver sinusoidal obstruction syndrome; Trastuzumab emtansine.
Similar articles
-
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report.BMC Cancer. 2019 Aug 6;19(1):774. doi: 10.1186/s12885-019-5986-5. BMC Cancer. 2019. PMID: 31387552 Free PMC article.
-
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.Breast Cancer Res Treat. 2019 Nov;178(2):473-477. doi: 10.1007/s10549-019-05393-8. Epub 2019 Aug 9. Breast Cancer Res Treat. 2019. PMID: 31399933
-
Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure.Cancer Treat Res Commun. 2021;27:100314. doi: 10.1016/j.ctarc.2021.100314. Epub 2021 Jan 20. Cancer Treat Res Commun. 2021. PMID: 33545569
-
The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.Crit Rev Oncol Hematol. 2019 Nov;143:20-26. doi: 10.1016/j.critrevonc.2019.07.010. Epub 2019 Aug 12. Crit Rev Oncol Hematol. 2019. PMID: 31449983 Review.
-
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27. J Oncol Pharm Pract. 2015. PMID: 24682654 Review.
Cited by
-
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance.Biomedicines. 2024 Apr 25;12(5):953. doi: 10.3390/biomedicines12050953. Biomedicines. 2024. PMID: 38790915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical